IRIS
Armenia, Daniele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 217
AS - Asia 207
NA - Nord America 122
SA - Sud America 109
AF - Africa 4
Totale 659
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 183
SG - Singapore 131
US - Stati Uniti d'America 111
BR - Brasile 106
CN - Cina 28
HK - Hong Kong 23
GB - Regno Unito 20
MX - Messico 7
BD - Bangladesh 6
DE - Germania 5
ID - Indonesia 5
CM - Camerun 3
NL - Olanda 3
TR - Turchia 3
UA - Ucraina 3
CA - Canada 2
IN - India 2
IQ - Iraq 2
JM - Giamaica 2
PK - Pakistan 2
RU - Federazione Russa 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AR - Argentina 1
EC - Ecuador 1
KE - Kenya 1
OM - Oman 1
PE - Perù 1
PL - Polonia 1
SA - Arabia Saudita 1
TW - Taiwan 1
Totale 659
Salva come PNG Salva come JPEG
Città #
Rome 181
Singapore 83
Santa Clara 37
Beijing 26
Hong Kong 20
Baltimore 8
Oxford 8
Belo Horizonte 7
Bicester 7
Buffalo 6
Mexico City 6
Rio de Janeiro 5
São Paulo 5
Secaucus 4
Brasília 3
Goiânia 3
Miami 3
Salvador 3
Volta Redonda 3
Caxias do Sul 2
Curitiba 2
Dhaka 2
Ipatinga 2
Juiz de Fora 2
Kingston 2
Ribeira do Pombal 2
Santa Maria 2
Sete Lagoas 2
São Gonçalo 2
São José dos Campos 2
Abu Dhabi 1
Almenara 1
Andorinha 1
Antakya 1
Aquiraz 1
Ariquemes 1
Arlington Heights 1
Ashburn 1
Assis 1
Bagé 1
Basra 1
Botucatu 1
Brunswick 1
Bryansk 1
Cabo Frio 1
Cambé 1
Campina Grande 1
Campinas 1
Candelária 1
Capela Nova 1
Cerquilho 1
Châteauguay 1
Cincinnati 1
Columbus 1
Contagem 1
Delhi 1
Diamantina 1
Dulles 1
Edison 1
Erbil 1
Estância 1
Florianópolis 1
Fort Worth 1
Fortaleza 1
Franca 1
Galloway 1
Guariba 1
Gujranwala 1
Hamilton 1
Iguape 1
Indaiatuba 1
Itaberaí 1
Itabira 1
Itapeva 1
Jaciara 1
Jandira 1
Jeddah 1
Joinville 1
La Plata 1
Leesburg 1
Leicester 1
Lima 1
Londrina 1
Los Angeles 1
Lucknow 1
Maceió 1
Madison 1
Magnesia ad Sipylum 1
Manaus 1
Mandaguari 1
Milan 1
Moline 1
Montreal 1
Mount Vernon 1
Muscat 1
Nairobi 1
New Iberia 1
Niterói 1
Ourinhos 1
Pancas 1
Totale 510
Salva come PNG Salva come JPEG
Nome #
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy 49
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21 28
Impact of baseline HIV-1 integrase polymorphisms on virological outcome in a large European cohort of patients starting a raltegravir-containing regimen 23
Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings 22
Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals 21
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice 18
Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study 17
Impact of HIV-1 subtypes and integrase natural polymorphisms on virological response to first-line integrase inhibitors based regimens 15
Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors 14
HIV MDR is still a relevant issue despite its dramatic drop over the years 14
CMV seroprevalence and coronary CMV-DNA detection in immunocompetent patients with heart diseases 13
A Very Low Geno2pheno False Positive Rate Is Associated with Poor Viro-Immunological Response in Drug-Naive Patients Starting a First-Line HAART 13
Emerging patterns and implications of HIV-1 integrase inhibitor resistance 12
Focus on recently developed assays for detection of resistance/sensitivity to reverse transcriptase inhibitors 12
Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease 12
Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals 12
Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients 11
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry 11
Evaluation of Viral Suppression in Paediatric Populations: Implications for the Transition to Dolutegravir-Based Regimens in Cameroon: The CIPHER-ADOLA Study 11
A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy 11
Does ultra-deep-sequencing in HCV patients treated with boceprevir/telaprevir-based therapy provide an added value in comparison to standard population-sequencing in the detection of resistance? 10
A high HBsAg genetic complexity can influence HBV immunogenicity in the setting of acute infection 10
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 10
Anti-HIV-1 activity of new integrase inhibitors in lymphocytes and human primary macrophages 10
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy 10
Genotypic Resistance Testing of HIV-1 DNA in Peripheral Blood Mononuclear Cells 10
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings 10
BASELINE/EARLY PRESENCE OF KNOWN AND NOVEL RESISTANCE MUTATIONS IS ASSOCIATED WITH VIRAL FAILURE IN DIFFICULT-TO-TREAT PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS 10
Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice 10
Darunavir (DRV)/r plus raltegravir (RAL) dual regimen in multi-experienced population: long term efficacy and tolerability 10
Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings 10
Secondary Integrase Resistance Mutations Found in HIV-1 Minority Quasispecies in Integrase Therapy-Naive Patients Have Little or No Effect on Susceptibility to Integrase Inhibitors 9
A high genetic heterogeneity in HBsAg can affect immunogenicity in acute hepatitis B infection 9
Hepatitis B Surface Antigen Genetic Elements Critical for Immune Escape Correlate With Hepatitis B Virus Reactivation Upon Immunosuppression 9
PRESTIGIO RING: "A 28-year-old highly treatmentexperienced man with vertical HIV infection on ibalizumab therapy: ART simplification perspectives" 8
IMPACT OF MUTATIONS AT POSITION 135 OF HIV-1 REVERSE TRANSCRIPTASE ON VIROLOGIC RESPONSE TO A FIRST LINE NNRTI-CONTAINING HAART 8
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens 8
Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV 8
Natural raltegravir-resistance is a rare event in integrase-inhibitors naive patients, and when present, is confined to a restricted minority of secondary variants and is not associated with virological response to raltegravir 8
P681 HBsAg MUTATIONS WITH ENHANCED CAPABILITY TO EVADE IMMUNE RESPONSE ARE ASSOCIATED WITH HBV REACTIVATION DURING IMMUNOSUPPRESSION 8
HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma 8
The Genotypic False Positive Rate Determined by V3 Population Sequencing Can Predict the Burden of HIV-1 CXCR4-using Species Detected by Pyrosequencing 8
HBsAg genetic elements critical for immune escape correlates with HBV reactivation upon immunosuppression 8
P696 A COMPLEX HBV QUASISPECIES IN RT AND HBsAg CHARACTERIZES PATIENTS WITH ACUTE HEPATITIS B: A REFINED UDPS ANALYSIS 7
Selection and coevolution of mutational patterns in the HIV-1 integrase characterized by pyrosequencing analysis 7
High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries 7
Tenofovir and Doravirine Are Potential Reverse-Transcriptase Analogs in Combination with the New Reverse-Transcriptase Translocation Inhibitor (Islatravir) Among Treatment-Experienced Patients in Cameroon: Designing Future Treatment Strategies for Low- and Middle-Income Countries 7
Study of Genotypic and Phenotypic HIV-1 Dynamics of Integrase Mutations During Raltegravir Treatment: A Refined Analysis by Ultra-Deep 454 Pyrosequencing 7
Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors 6
The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype 6
P0580 : Genetic signatures specifically clustered in immune active HBsAg regions correlate with immunosuppression-driven HBV reactivation: An extensive analysis of HBV genome 6
HIV-1 INTEGRASE MUTATIONS, FOUND AS MINORITY QUASISPECIES IN PATIENTS NAIVE TO INTEGRASE INHIBITORS, ARE ASSOCIATED WITH DECREASED SUSCEPTIBILITY TO RALTEGRAVIR AND ELVITEGRAVIR IN VITRO 6
Impact of pre-therapy viral load on virological response to modern first-line HAART 6
Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database 6
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia 5
Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers 5
HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBVcoinfected patients on first-line therapy 5
Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage 5
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 5
Reliability and Clinical Relevance of the HIV-1 Drug Resistance Test in Patients With Low Viremia Levels 5
Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients 5
P0915 : Clinical relevance of baseline/early detection and persistence of resistant associated variants in HCV-1 patients treated with protease-inhibitors assessed by ultra-deep sequencing 5
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. 5
Ultradeep sequencing detection of the R263K integrase inhibitor drug resistance mutation 4
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 4
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 4
Virological response and resistance in multi-experienced patients treated with raltegravir 4
Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients With Acute Hepatitis B 4
THE LOWEST X4 GENO2PHENO-FALSE POSITIVE RATE IS ASSOCIATED WITH GREATER CD4-DEPLETION 4
Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. 4
Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children. 4
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro. 4
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen 3
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice 3
Totale 706
Salva come PNG Salva come JPEG
Categoria #
all - tutte 2.137
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.137
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20242 0 0 0 0 0 0 0 0 0 0 0 2
2024/2025704 55 0 12 104 17 11 101 97 45 28 176 58
Totale 706